ECD Proteins
SKU: PME-C100059 Target: ROR2
Price: 10μg $112.00; 50μg $409.00 ; 100 μg $614.00
ECD Proteins
SKU: PME-C100011 Target: BTN3A1
Price:10μg $120.00; 50μg $380.00; 100μg $570.00
ECD Proteins
SKU: PME-C100002 Target: CXCL10
Price: 10μg $100.00 ; 50μg $375.00 ; 100 μg $550.00
ECD Proteins
SKU: PME-C100033 Target: CEACAM5
Price:10μg $120.00; 50μg $380.00; 100μg $570.00
ECD Proteins
SKU: PME-C100019 Target: TNFSF15
Price:10μg $95.00; 50μg $330.00; 100μg $500.00
ECD Proteins
SKU: PME-C100078 Target: SLITRK6
Price: 10μg $100.00 ; 50μg $358.00 ; 100μg $528.00
ECD Proteins
SKU: PME-C100050 Target: CLDN18.2
Price: 10μg $118.00; 50μg $409.00 ; 100 μg $615.00
ECD Proteins
SKU: PME-C100045 Target: NECTIN4
Price: 10μg $118.00; 50μg $429.00 ; 100 μg $645.00
ECD Proteins
SKU: PME-C100039 Target: Mesothelin
Price: 10μg $118.00; 50μg $409.00 ; 100 μg $615.00
ECD Proteins
SKU: PME-C100071 Target: GPC3
Price: 10μg $120.00 ; 50μg $450.00 ; 100 μg $660.00
ECD Proteins
SKU: PME-C100068 Target: MUC1
Price:10μg $81.00 ; 50μg $296.00 ; 100μg $444.00
ECD Proteins
SKU: PME-C100072 Target: GPC3
Price: 10μg $120.00 ; 50μg $450.00 ; 100 μg $660.00
ECD Proteins
SKU: PME-C100073 Target: GPC3
Price: 10μg $120.00 ; 50μg $450.00 ; 100 μg $660.00
ECD Proteins
SKU: PME100561 Target: GPRC5D
Price: 10μg $72.00; 50μg $272.00; 100μg $409.00
ECD Proteins
SKU: PME-C100070 Target: MUC1
Price:10μg $81.00 ; 50μg $296.00 ; 100μg $444.00
ECD Proteins
SKU: PME-C100069 Target: MUC1
Price:10μg $81.00 ; 50μg $296.00 ; 100μg $444.00
ECD Proteins
SKU: PME-C100066 Target: DLL3
Price: 10μg $82.00; 50μg $320.00 ; 100 μg $480.00
ECD Proteins
SKU: PME-C100065 Target: DLL3
Price: 10μg $82.00; 50μg $320.00 ; 100 μg $480.00
ECD Proteins
SKU: PME-C100064 Target: DLL3
Price: 10μg $82.00; 50μg $320.00 ; 100 μg $480.00
ECD Proteins
SKU: PME-C100063 Target: DLL3
Price: 10μg $82.00; 50μg $320.00 ; 100 μg $480.00
Posts found
PSMA: A Key Target for Radiotherapy and Diagnosis in Prostate Cancer
Prostate-specific membrane antigen (PSMA) is a pivotal molecular target in the treatment and diagnosis of [...]
Dec
CD73: A Potential Target in Cancer Immunotherapy
On September 25, 2024, I-Mab announced a strategic collaboration with Sanofi to develop, produce, and [...]
Oct
HER3/ERBB3: Dominating Cancer Therapy with ADCs and Beyond
On September 17, a collaboration between Daiichi Sankyo and Merck announced that patritumab deruxtecan, a [...]
Sep
Research Progress on BCMA-Targeted Therapies in Multiple Myeloma
On August 27, 2024, Legend Biotech’s BCMA CAR-T product, Carvykti® (generic name: ciltacabtagene autoleucel injection), [...]
Sep
Research Progress on Targeting BCMA in Autoimmune Diseases
The B cell maturation antigen (BCMA), a target that gained prominence due to its association [...]
Aug
The Fate of ADAM9 ADCs: What Lies Ahead After AbbVie’s Decision?
In March 2024, AbbVie announced its decision to terminate the development of IMGC936 in collaboration [...]
Aug
CDH6 ADC: Promising Results for Ovarian Cancer Treatment!
In March 2024, a preclinical study titled “Raludotatug Deruxtecan, a CDH6-Targeting Antibody–Drug Conjugate with a [...]
Jul
Nectin-4: A Promising Target in Antibody-Drug Conjugate (ADC) Therapy
During the 2024 ASCO conference, Professor Zhang Jian of Fudan University’s Cancer Hospital unveiled the [...]
Jun
FRα/FOLR1 – Another Anti-cancer Target Fueled by the ADC
Folate receptor alpha (FRα), due to its differential expression in various tumor or cancer tissues [...]
May
Immune Checkpoint B7-H3: Exploring the Current Landscape of Targeted Therapies
In December 2023, GlaxoSmithKline (“GSK”) invested $1.71 billion to obtain the global exclusive rights for [...]
May